Pfizer (NYSE:PFE) Gets CDC Recommendation to Expand ABRYSVO Vaccine Use for RSV Prevention
Pfizer recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at increased risk. Despite this positive development, Pfizer's shares saw a 2% decline over the past week. This move is in line with broader market trends, as the market dropped by 3% during the same period. The company's decision to halt development of Danuglipron, an oral weight loss drug, due to safety concerns, may have also added weight to the downward pressure on its shares, amid wider concerns impacting the healthcare sector and investor sentiment surrounding safety in drug development.
Pfizer has 3 possible red flags (and 2 which shouldn't be ignored) we think you should know about.
We've found 28 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
The recent CDC recommendation for Pfizer's RSV vaccine, ABRYSVO, is a promising development that could positively impact the company's revenue and earnings forecasts; however, the decision to halt development of the Danuglipron weight loss drug amplifies concerns over safety in drug development. This mix of news, coupled with Pfizer's shift towards enhancing R&D productivity, could moderate future growth expectations as ongoing savings measures aim to boost margins. Investors might anticipate a measured but cautious optimism as outcomes of these initiatives unfold.
Over the past year, Pfizer's total shareholder return stands at a 7.86% decline, underperforming the broader US market, which posted a 4.6% gain. Compared to the US Pharmaceuticals industry, which experienced an 8% decrease, Pfizer also lagged slightly. The price movement aligns somewhat with the bears' price target of $25.56, which remains 13.8% above the current share price of $22.04, indicating some market skepticism about reaching consensus targets of $30.45. As Pfizer faces pressures from legislative changes impacting revenue, careful monitoring of pipeline developments and cost strategies will be crucial to adapting earnings forecasts going forward.
Our valuation report here indicates Pfizer may be undervalued.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NYSE:PFE.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Cosmetics Industry Icon Leonard A. Lauder, Chairman Emeritus, The Estée Lauder Companies, Passes Away
NEW YORK--(BUSINESS WIRE)--It is with deep sadness that The Estée Lauder Companies Inc. (NYSE: EL) announces that Chairman Emeritus Leonard A. Lauder passed away on June 14, at the age of 92, surrounded by family. Mr. Lauder was born in 1933 in New York City, the oldest son of Estée and Joseph H. Lauder, the founders of The Estée Lauder Companies. He was a graduate of the Bronx High School of Science, the University of Pennsylvania's Wharton School, and the Officer Candidate School of the United States Navy. Mr. Lauder studied at Columbia University's Graduate School of Business. He served as a lieutenant in the U.S. Navy and as a Navy reservist, for which the U.S. Navy Supply Corps Foundation later recognized him with its Distinguished Alumni Award. He formally joined Estée Lauder in 1958, and for more than six decades, Mr. Lauder was a visionary and an innovator, helping transform the business from a handful of products sold under a single brand in U.S. stores to the multi-brand, global leader in prestige beauty that it is today. 'Throughout his life, my father worked tirelessly to build and transform the beauty industry, pioneering many of the innovations, trends, and best practices that are foundational to the industry today,' said William P. Lauder, son and Chair, Board of Directors, The Estée Lauder Companies. 'He was the most charitable man I have ever known, believing that art and education belonged to everyone, and championing the fight against diseases such as Alzheimer's and breast cancer. Above all, my father was a man who practiced kindness with everyone he met. His impact was enormous. He believed that employees were the heart and soul of our company, and they adored him and moments spent with him. His warmth and thoughtfulness made an imprint on our company, the industry, and, of course, our family. Together with my family, The Estée Lauder Companies, and the countless people he touched, we celebrate his extraordinary life.' Mr. Lauder served as President of The Estée Lauder Companies from 1972 to 1995 and as Chief Executive Officer from 1982 through 1999. He was named Chairman in 1995 and served in that role through June 2009. Throughout his tenure at the company, Mr. Lauder consistently challenged the status quo, developing and implementing innovative sales and marketing programs that revolutionized the beauty industry. He created the company's first research and development laboratory, brought in professional management at every level, and was the driving force behind The Estée Lauder Companies' international expansion, helping to increase the company's sales and profits exponentially. A legendary brand builder, Mr. Lauder led the launch of many brands including Aramis, Clinique, and Lab Series, among others. Until his death, he remained deeply involved in the company's acquisition strategy, including the acquisitions of Aveda, Bobbi Brown, Jo Malone London, La Mer, and M∙A∙C. Speaking for The Estée Lauder Companies, President and Chief Executive Officer Stéphane de La Faverie said, 'Leonard Lauder was beloved by many and will be missed tremendously. To our employees at The Estée Lauder Companies, he was an inspiration and a champion. To the industry, he was an icon and pioneer, earning respect worldwide. His energy and vision helped shape our company and will continue to do so for generations to come. He was a deeply compassionate leader who cared profoundly about every person in the company. I feel privileged to have worked with Leonard, who has been the best mentor I could have dreamt to learn from. He will be remembered by all of us.' During his many years as Chairman Emeritus, Mr. Lauder was closely involved in the business and day-to-day operations of the company and was a constant fixture at The Estée Lauder Companies' global headquarters in New York and at our stores and counters across the globe until the time of his death. Mr. Lauder believed that each of his colleagues was like a member of his family and treated them as such. The values that continue to set the company apart are the values he so strongly believed in and embodied, most notably generosity of spirit and kindness toward all. Perhaps the role Mr. Lauder was most proud of was the unofficial one as The Estée Lauder Companies' 'chief teaching officer.' He believed that a company's wealth is its people and focused on mentoring and fostering growth within the company's diverse talent pool. He believed strongly in the importance of recognition and gratitude and was a tireless advocate for employees. At the onset of the global pandemic in 2020, Mr. Lauder was instrumental in setting up the ELC Cares Employee Relief Fund to support the physical, mental, and emotional well-being of employees and their families. Mr. Lauder was deeply involved in medical research, education, art, foreign policy, and philanthropy, and the marks he made on those worlds were transformational. Mr. Lauder believed passionately in the importance of public access to art and museums, which inspired his philosophy that the primary role of a collector was to conserve, not possess. He was a long-time supporter of the Metropolitan Museum of Art (the Met) and, in 2013, pledged his 78-piece collection of Cubist art to the museum in the largest single philanthropic gift in the Met's history. He later added five major works to that promised gift. In concert with his Cubist collection donation, he helped establish the Leonard A. Lauder Research Center for Modern Art at the Met to support a robust program of fellowships, focused exhibitions, and public lectures. Along with his prominent presence at the Met, he also served as the Whitney Museum of American Art's Chairman Emeritus and a trustee from 1977 to 2011. Throughout his life, he donated works of art and endowed curatorial positions and research departments to numerous institutions. Mr. Lauder was a long-time advocate of cancer research and served as Honorary Chairman of the board of directors at the Breast Cancer Research Foundation, the organization his beloved late-wife, Evelyn H. Lauder, founded in 1993. He also championed the fight against Alzheimer's by co-founding and leading the Alzheimer's Drug Discovery Foundation with his brother, Ronald S. Lauder, which supports cutting-edge drug research. Mr. Lauder remained actively engaged with these organizations until his death, and they were extraordinarily dear to his heart. Remembering his brother, Ronald S. Lauder, Chairman, Clinique Laboratories, LLC at The Estée Lauder Companies, said, 'Leonard was a wonderful brother and a devoted husband, father, grandfather, great-grandfather, uncle, colleague, and friend. But his legacy extends far beyond being the heart of our family. His impact will be felt for generations to come thanks to his tireless philanthropy, advocacy, and creativity in tackling some of the world's greatest challenges. The number of lives he touched and positively impacted across all his endeavors is immeasurable. His passion and generosity have inspired us all, and there are no words to express how much he will be missed.' 'My father was a remarkable man, a leader in business, a devoted philanthropist, and a deeply loving father, grandfather, and great-grandfather,' said Gary M. Lauder, son and Member, Board of Directors, The Estée Lauder Companies. 'His energy, sharp intellect, and generous spirit touched the lives of so many across the world. To me, he was also a constant source of encouragement, wisdom, and love. His legacy is vast, not only in the beauty industry, but in the countless lives improved by his charitable efforts and his passionate commitment to the arts, education, and healthcare. He was not only well-respected and admired, but he was also adored by his employees and colleagues. This affection stands out for me. While we mourn his passing, we also celebrate his extraordinary life, his lasting contributions, and the values he instilled in all of us: integrity, curiosity, and the importance of giving back. He will be missed more than words can express.' Mr. Lauder believed in the value of education and supported a variety of academic institutions. He was an emeritus trustee of the University of Pennsylvania and a founding member of the board of governors of its Joseph H. Lauder Institute of Management and International Studies, along with his brother, Ronald. His passion for education continued into the public space, having supported several schools in the New York area and receiving the honor of being an inductee into the Bronx High School of Science Hall of Fame in 2017. When the pandemic in 2020 magnified the nation's acute shortage of quality primary care in underserved communities, Mr. Lauder worked with the University of Pennsylvania to create a tuition-free program to educate nurse practitioners. His donation of $125 million, the largest gift ever to an American nursing school, made possible the Leonard A. Lauder Community Care Nurse Practitioner Program at the University of Pennsylvania. Mr. Lauder worked throughout his life to promote dialogue among governments, political and non-governmental organizations, and the public and private sectors, believing that this interdisciplinary dialogue is crucial to progress. He served as a member of the Council on Foreign Relations and as Chairman Emeritus and a lifetime trustee on the board of directors at the Aspen Institute. He felt that public service was a person's duty and, in addition to his time in the U.S. Navy, later served on the Advisory Committee for Trade Negotiations under President Ronald Reagan from 1983–1987. Throughout his lifetime, Mr. Lauder was honored with a myriad of awards, including the 'Lone Sailor' Award given by the U.S. Navy Supply Corps Foundation, the Légion d'Honneur given by the government of France, the Women's Leadership Award given by the Lincoln Center Corporate Fund Women's Leadership Council, and the Palazzo Strozzi Renaissance Man of the Year Award. In 2020, he was inducted into the Retail Hall of Fame by the World Retail Congress. The Lauder family received the esteemed 2011 Carnegie Medal of Philanthropy in recognition of its long-standing commitment to philanthropy and public service. In 2014, Mr. Lauder was named a Living Landmark by the New York Landmarks Conservancy. Mr. Lauder and Ms. Glickman Lauder also received the Gordon Parks Foundation Patron of the Arts Award in 2016. Mr. Lauder shared many of the lessons he learned in business and life in his memoir, The Company I Keep: My Life in Beauty, published to great acclaim in 2020. He was married to Evelyn H. Lauder, Senior Corporate Vice President at The Estée Lauder Companies and the Founder of the Breast Cancer Research Foundation, from 1959 until she passed away in 2011. On January 1, 2015, Mr. Lauder married Judy Glickman Lauder, a philanthropist and internationally recognized photographer whose work is represented in more than 300 public and private collections, including the J. Paul Getty Museum, the Whitney Museum of Art, the Metropolitan Museum of Art, and the United States Holocaust Museum. Mr. Lauder considered himself lucky in love and believed that lightning really could strike twice. From the beginning, he was devoted to family. He loved his parents and adored his brother, Ronald, and the family Ronald built with Jo Carole. His nieces and their families held a special place in his heart. Mr. Lauder was grateful to his wife, Judy, for widening his family circle and cherished his stepchildren and their families. But mostly, he was extraordinarily proud of both of his sons, their families, and his grandchildren and great-grandchildren. He loved them so dearly. Mr. Lauder was a true visionary, fearless leader, and cherished friend to so many. He was the beacon of our company and the north star of an entire industry. The world is a better place because Leonard Lauder was in it. The Estée Lauder Companies extends our deepest sympathies to the entire Lauder family during this exceedingly difficult time. Mr. Lauder is survived by his wife, Judy Glickman Lauder; his son William P. Lauder; his son Gary M. Lauder and wife, Laura Lauder; five grandchildren, Rachel, Danielle, Djuna-Bear, Joshua, Eliana, two great-grandchildren, many stepchildren and step grandchildren, as well as his brother, Ronald S. Lauder, and wife, Jo Carole Lauder, and their daughters, Aerin Lauder and Jane Lauder. A private service will be held for friends and family. For those who wish, in lieu of flowers, memorial donations may be made to the Breast Cancer Research Foundation and the Alzheimer's Drug Discovery Foundation. The Estée Lauder Companies Inc. (ELC) is one of the world's leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company's products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.
Yahoo
3 hours ago
- Yahoo
Amazon Signs 141,000 Square Foot We Work Lease In Silicon Valley Amid Relentless Expansion And Back To Work Mandate
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Amazon's (NASDAQ:AMZN) office expansion knows no bounds. Fresh from expanding its presence in New York, the tech giant announced it is growing its presence in Silicon Valley by teaming up with WeWork (NYSE:WE) to add 141,000 square feet of office space to accommodate its return-to-office mandate, CoStar News reports. The new offices are located at 4980 Great America Parkway in Santa Clara, California, in a building that Amazon will occupy in its entirety as part of its effort to have its workforce return to a five-day-per-week in-office work schedule. 'We're constantly evaluating our office footprint based on the needs of Amazon's businesses,' an Amazon spokesperson told CoStar News. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can WeWork has been a constant collaborator with Amazon, and the most recent deal follows similar arrangements the two companies have made recently, CosStar reports. At 330 W. 34th St. in New York and at 401 San Antonio Road in Mountain View, California, WeWork signed an office lease before Amazon moved in. 'So if we look at it and just take today's environment with all the uncertainty around tariffs and what's happening, who's prepared to commit to a 10- or a 15-year lease with $50 or $100 million spend?' WeWork CEO, John Santora, said of the arrangement with Amazon and other companies at a recent summit. 'You have to think about it. You have to think whether or not to invest that major capital in a market, at least through this short term. You have to step back,' he told Bloomberg. Trending: Invest Where It Hurts — And Help Millions Heal: While back-to-work mandates have been popular amongst many major corporations this year, Amazon has struggled to implement their's due to a lack of office space. Workers in Dallas, Phoenix, Atlanta and New York had their deadlines to return to the office pushed back four months while Amazon acquired more space. Amazon CEO Andy Jassy told employees in September that returning to an in-office work regimen was vital because 'collaborating, brainstorming and inventing are simpler and more effective.' 'If it's not for you, then that's OK. You can go and find another company if you want to. But for us, that's what we've decided is the best way to operate our company,' Amazon Web Services CEO Matt Garman said at a Wall Street Journal event in return-to-office push has not been without its complications, with parking space and commuting being among the complaints from former remote workers, the Journal reported. 'While we've heard ideas for improvement from a relatively small number of employees and are working to address those, these anecdotes don't reflect the sentiment we're hearing from most of our teammates,' a company spokeswoman told the Journal in February. 'What we're seeing is great energy across our offices.' On June 9 Pennsylvania Gov. Josh Shapiro announced that Amazon planned to invest 'at least $20 billion to establish multiple high-tech cloud computing and artificial intelligence (AI) innovation campuses across the Commonwealth of Pennsylvania.' The push would create 'at least 1,250 high-paying, high-tech jobs. Salem Township and Falls Township are the first communities identified as sites for these future campuses,' he said in a statement. It marks the largest capital investment in the commonwealth's history. Read Next: With Point, you can Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Image: Shutterstock This article Amazon Signs 141,000 Square Foot We Work Lease In Silicon Valley Amid Relentless Expansion And Back To Work Mandate originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Pfizer Inc. (NYSE:PFE) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Pfizer's (NYSE:PFE) stock is up by a considerable 7.5% over the past month. However, we decided to pay attention to the company's fundamentals which don't appear to give a clear sign about the company's financial health. Specifically, we decided to study Pfizer's ROE in this article. ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Return on equity can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Pfizer is: 8.7% = US$7.9b ÷ US$91b (Based on the trailing twelve months to March 2025). The 'return' is the amount earned after tax over the last twelve months. One way to conceptualize this is that for each $1 of shareholders' capital it has, the company made $0.09 in profit. Check out our latest analysis for Pfizer We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics. When you first look at it, Pfizer's ROE doesn't look that attractive. A quick further study shows that the company's ROE doesn't compare favorably to the industry average of 19% either. Therefore, it might not be wrong to say that the five year net income decline of 6.5% seen by Pfizer was probably the result of it having a lower ROE. We reckon that there could also be other factors at play here. For instance, the company has a very high payout ratio, or is faced with competitive pressures. However, when we compared Pfizer's growth with the industry we found that while the company's earnings have been shrinking, the industry has seen an earnings growth of 9.0% in the same period. This is quite worrisome. Earnings growth is an important metric to consider when valuing a stock. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. Is Pfizer fairly valued compared to other companies? These 3 valuation measures might help you decide. In spite of a normal three-year median payout ratio of 35% (that is, a retention ratio of 65%), the fact that Pfizer's earnings have shrunk is quite puzzling. So there might be other factors at play here which could potentially be hampering growth. For example, the business has faced some headwinds. Additionally, Pfizer has paid dividends over a period of at least ten years, which means that the company's management is determined to pay dividends even if it means little to no earnings growth. Looking at the current analyst consensus data, we can see that the company's future payout ratio is expected to rise to 58% over the next three years. However, Pfizer's future ROE is expected to rise to 17% despite the expected increase in the company's payout ratio. We infer that there could be other factors that could be driving the anticipated growth in the company's ROE. On the whole, we feel that the performance shown by Pfizer can be open to many interpretations. While the company does have a high rate of reinvestment, the low ROE means that all that reinvestment is not reaping any benefit to its investors, and moreover, its having a negative impact on the earnings growth. Having said that, looking at current analyst estimates, we found that the company's earnings growth rate is expected to see a huge improvement. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
